What a GLP-1 evaluation may include

Why the evaluation matters

GLP-1 treatment decisions are not only about weight. They involve medication safety, labeled indications, contraindications, other medical conditions and whether follow-up can happen reliably. Wegovy and Zepbound labels both include boxed warnings about thyroid C-cell tumors observed in rodents. The labels say it is unknown whether these drugs cause medullary thyroid carcinoma in humans, and they contraindicate use in people with a personal or family history of medullary thyroid carcinoma or MEN 2 Wegovy label Zepbound label.

The evaluation gives the clinician a structured way to look for those issues before treatment starts.

Medical history and medication review

Expect questions about current diagnoses, prior surgeries, pregnancy, breastfeeding questions, pregnancy plans, contraception, diabetes, pancreatitis, gallbladder disease, kidney problems, personal or family history of medullary thyroid carcinoma, MEN 2 or other thyroid history requested by the clinician, and other weight-related conditions. Medication review is just as important because insulin, sulfonylureas or other diabetes medicines, gastrointestinal side effects and other prescriptions can change the risk discussion. Wegovy and Zepbound labels warn about increased hypoglycemia risk when used with insulin or insulin secretagogues Wegovy label Zepbound label.

If you have recent labs or primary-care records, they may help the clinician understand the starting point. If you do not, the clinician may still be able to decide what information is needed next.

The visit format may depend on the case

Some evaluations can begin with structured intake questions. Others may need a live visit, additional records, labs or in-person care. The right format depends on the patient’s state, symptoms, medical complexity and the clinician’s judgment.

A patient should not interpret a request for more information as a failure. It may be the step that lets the clinician make a safer decision, especially when the history includes diabetes medications, severe gastrointestinal symptoms, possible pregnancy, oral hormonal contraceptive use, prior pancreatitis or unclear pharmacy records. Wegovy labeling says weight loss offers no benefit during pregnancy and may cause fetal harm; Zepbound labeling includes specific advice for patients using oral hormonal contraceptives after starting or escalating dose Wegovy label Zepbound label.

How to prepare for the evaluation

Preparation can make the review more useful. Write down your current prescriptions, supplement use, medication allergies, prior weight-management treatments, recent side effects and any questions about product type or pharmacy fulfillment. If you use insulin or another diabetes medication, say so clearly.

It also helps to name your main goal in plain language. A clinician may still focus first on safety and fit, but clear goals can shape the follow-up conversation and help separate realistic treatment monitoring from unsupported outcome expectations.

Product questions belong in the evaluation

The evaluation is also the right time to ask what product is being considered. Ask whether the medication is an FDA-approved finished product or a compounded preparation. FDA says compounded drugs are not FDA-approved and should not be marketed as generic versions or the same as approved products FDA telehealth compounding reminders.

A clear answer should name the active ingredient, product type, route, dosage form and pharmacy path. If those facts are not clear, pause and ask.

Possible outcomes of the review

• The clinician may decide treatment is appropriate and write a prescription.
• The clinician may ask for more information, labs or records.
• The clinician may recommend a different treatment plan or in-person care.
• The clinician may decide GLP-1 treatment is not appropriate.

Each outcome is still care. A careful no can be as important as a prescription when the medical history does not fit the treatment.

Common questions